Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,728 across all filing types
Latest filing 2014-03-13 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
审计与风险控制委员会2013年度履职报告
Audit Report / Information Classification · 95% confidence The document is titled as the 'Audit and Risk Control Committee 2013 Annual Performance Report' of Kunming Pharmaceutical Group Co., Ltd. It details the activities and meetings of the audit committee throughout 2013, including review and approval of quarterly and annual financial reports, interaction with the external auditor, and oversight of the audit process. The document focuses on the audit committee's duties and their fulfillment during the year, rather than presenting the full annual report or financial statements themselves. The length is under 5,000 characters and it is a committee report on audit and risk control activities, which aligns with the definition of an Audit Report / Information (AR) filing rather than a full Annual Report (10-K) or other categories. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2013
2014-03-13 Chinese
关于昆明制药集团股份有限公司2013年度非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 95% confidence The document is an audit-related special explanation regarding non-operating fund occupation and other related party fund transactions for the year 2013 of Kunming Pharmaceutical Group Co., Ltd. It references an audit report issued on March 12, 2014, and includes detailed financial data tables about related party transactions and fund usage. The document is not a full annual report but a standalone audit-related disclosure focusing on specific financial audit matters and compliance with regulatory requirements. It contains substantive financial data and audit findings but is not a general financial report or earnings release. Therefore, it fits the category of Audit Report / Information (AR). The document length (7759 characters) supports it being a detailed report rather than a brief announcement or certification.
2014-03-13 Chinese
2013年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2013年度募集资金存放与使用情况的专项报告" which translates to "2013 Annual Special Report on the Deposit and Use of Raised Funds." It details the company's fundraising activities, including initial public offering and additional share issuance, the management and use of raised funds, investment projects, and related audit and verification reports by accounting firms and sponsors. The document includes detailed financial figures and compliance with regulatory requirements regarding the use of raised funds. It is a specialized report focusing on the management and use of capital raised through equity issuance, not a general annual report or earnings release. This type of document fits best under the category of Capital/Financing Update (CAP), as it provides updates on fundraising activities and the use of those funds. The document length (6670 characters) and detailed financial data support this classification rather than a simple announcement or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2014-03-13 Chinese
关于召开2013年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a notice for the 2013 Annual General Meeting (AGM) of Kunming Pharmaceutical Group Co., Ltd., detailing the meeting time, location, agenda items including reports and proposals to be voted on, voting methods including online voting, and instructions for shareholders. It does not contain the actual annual report or financial statements but rather the announcement and procedural information for the AGM. The document length is under 5,000 characters and is clearly a meeting notice rather than the report itself. Therefore, it fits the category of AGM Information (AGM-R).
2014-03-13 Chinese
关于为子公司昆明制药集团医药商业有限公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding providing a guarantee for its subsidiary, Kunming Pharmaceutical Group Medical Commerce Co., Ltd. It details the guarantee amount, the subsidiary's financial status, the board's opinion, and the need for shareholder approval. The document is short (1287 characters) and focuses on a specific financing-related guarantee event rather than a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but is an announcement of a capital/financing update related to guarantees. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2014-03-13 Chinese
招商证券股份有限公司关于昆明制药集团股份有限公司变更部分募投项目实施地点的保荐意见
Capital/Financing Update Classification · 95% confidence The document is a formal opinion from a sponsoring securities company (招商证券股份有限公司) regarding the change of implementation locations for certain fundraising investment projects of Kunming Pharmaceutical Group Co., Ltd. It references regulatory rules from the Shanghai Stock Exchange and details about the use of funds raised from a public stock issuance in 2013. The document includes a detailed explanation of the project changes, approvals, and the sponsor's verification and opinion. It is not a full financial report, earnings release, or management discussion, but rather a regulatory compliance and sponsor opinion document related to capital use and project location changes. The document length is 2492 characters, which is relatively short and focused on a specific regulatory opinion. This fits best under Capital/Financing Update (CAP) as it concerns changes in the use of raised capital and project implementation details, with a formal sponsor opinion. It is not an announcement of a report publication, nor a general regulatory filing, but a specific update on capital project changes with sponsor endorsement.
2014-03-13 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.